Inventor · disambiguated record
Lynn Kirkpatrick
Also filed as: KIRKPATRICK LYNN · KIRKPATRICK LYNN D
6 granted patents·13 pending applications·65 citations·filing 1994–2025
81Inventor score
Top patents by PatentIndex Score
19 records- 0188US7446124B2Wortmannin analogs and methods of using same in combination with chemotherapeutic agentsPROLX PHARMACEUTICALS CORP·Filed 2005·Granted Nov 4, 2008·12 cites·25 claims
- 0285US5602278AN-oxides and derivatives of chlorambucil for treating hypoxic tumor cellsFiled 1994·Granted Feb 11, 1997·33 cites·13 claims
- 0383US7399785B2N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factorPROLX PHARMACEUTICALS CORP·Filed 2004·Granted Jul 15, 2008·18 cites·19 claims
- 0481US7858657B2Wortmannin analogs and methods of using same in combination with chemotherapeutic agentsPROLX PHARMACEUTICALS CORP·Filed 2008·Granted Dec 28, 2010·1 cites·8 claims
- 0568US12384744B2Enzyme-cleavable methadone prodrugs and methods of use thereofENSYSCE BIOSCIENCES INC·Filed 2022·Granted Aug 12, 2025·0 cites·3 claims
- 0662US7629128B2Methods of identifying respondents to hypoxia inducible factor 1-α inhibitorsPROLX PHARMACEUTICALS CORP·Filed 2006·Granted Dec 8, 2009·1 cites·5 claims
- 0762US2025361205A1Enzyme-cleavable methadone prodrugs and methods of use thereofENSYSCE BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 0856US2010105072A1Methods of identifying respondents to hypoxia inducible factor 1-alpha inhibitorsKIRKPATRICK LYNN·Filed 2009·Application pending·0 cites
- 0956US2011110941A1Wortmannin Analogs and Methods of Using Same in Combination with Chemotherapeutic AgentsPROLX PHARMACEUTICALS CORP·Filed 2010·Application pending·0 cites
- 1050US2022287975A1Modified release compositions of nafamostat and methods of using sameENSYSCE BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 1149US2005049309A1Regulation of HIF protein levels via deubiquitination pathwayFiled 2004·Application pending·0 cites
- 1248US2018036374A1Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related TheretoENSYSCE BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 1347US2006104902A1Method of preselection patients for anti-VEGF, anti-HIF-1 or anti-thioredoxin therapyPOWIS GARTH·Filed 2005·Application pending·0 cites
- 1445US2023190697A1Methods for treating viral infections with nafamostatENSYSCE BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 1543US2016228544A1Single Walled Carbon Nanotube Polynucleotide Complexes and Methods Related TheretoENSYSCE BIOSCIENCES INC·Filed 2016·Application pending·0 cites
- 1643US2010166724A1Uses of thioredoxinPOWIS GARTH·Filed 2010·Application pending·0 cites
- 1742US2004087556A1N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factorFiled 2002·Application pending·0 cites
- 1839US2004116496A1Asymmetric Disulfides and methods of using sameKIRKPATRICK LYNN·Filed 2003·Application pending·0 cites
- 1938US2012114710A1Carbon nanotubes complexed with multiple bioactive agents and methods related theretoKIRKPATRICK LYNN·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →